CollPlant Biotechnologies (NASDAQ:CLGN) Earns Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research note released on Wednesday,Benzinga reports. D. Boral Capital currently has a $12.00 price objective on the stock.

CollPlant Biotechnologies Trading Up 5.0%

Shares of NASDAQ CLGN opened at $2.52 on Wednesday. CollPlant Biotechnologies has a one year low of $1.31 and a one year high of $5.45. The firm has a market capitalization of $32.05 million, a PE ratio of -2.23 and a beta of 1.47. The business has a 50-day moving average price of $2.01 and a two-hundred day moving average price of $2.43.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Wednesday, August 20th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.57). CollPlant Biotechnologies had a negative return on equity of 94.08% and a negative net margin of 541.34%.The business had revenue of $0.18 million for the quarter, compared to analyst estimates of $8.91 million. Research analysts anticipate that CollPlant Biotechnologies will post -1.44 EPS for the current year.

Institutional Investors Weigh In On CollPlant Biotechnologies

A number of institutional investors have recently bought and sold shares of the business. Villere ST Denis J & Co. LLC boosted its position in CollPlant Biotechnologies by 13.0% during the 2nd quarter. Villere ST Denis J & Co. LLC now owns 546,867 shares of the company’s stock worth $744,000 after acquiring an additional 63,000 shares during the period. Pinnacle Associates Ltd. boosted its position in CollPlant Biotechnologies by 3.7% during the 2nd quarter. Pinnacle Associates Ltd. now owns 507,193 shares of the company’s stock worth $690,000 after acquiring an additional 18,000 shares during the period. AMH Equity Ltd boosted its position in CollPlant Biotechnologies by 28.7% during the 2nd quarter. AMH Equity Ltd now owns 160,849 shares of the company’s stock worth $219,000 after acquiring an additional 35,849 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of CollPlant Biotechnologies during the 4th quarter valued at about $38,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after buying an additional 4,405 shares during the last quarter. 21.69% of the stock is currently owned by institutional investors and hedge funds.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.